MX364312B - Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a. - Google Patents
Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a.Info
- Publication number
- MX364312B MX364312B MX2015013291A MX2015013291A MX364312B MX 364312 B MX364312 B MX 364312B MX 2015013291 A MX2015013291 A MX 2015013291A MX 2015013291 A MX2015013291 A MX 2015013291A MX 364312 B MX364312 B MX 364312B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- virus
- composition
- neutralizing
- binding molecules
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 2
- 241000712431 Influenza A virus Species 0.000 abstract 3
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 239000000185 hemagglutinin Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000037797 influenza A Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
Abstract
La presente invención se refiere a una composición que comprende por lo menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza A, que aglutinan un epítope dentro de una región troncal de una proteína hemaglutinina (HA) de un virus de influenza A; donde la composición comprende: i) una primera molécula aglutinadora que puede neutralizar por lo menos un subtipo del virus de influenza A seleccionado del grupo formado por H1, H2, H5 y H9; ii), una segunda molécula aglutinadora que puede neutralizar por lo menos un subtipo de virus de influenza A seleccionado del grupo formado por H1, H3, H5, H7 y H9. La composición mixta de la presente invención neutraliza efectivamente ambos subtipos de influenza múltiples de los grupos filógenos 1 y 2, y se puede usar junto con compuestos químicos y, por lo tanto, es muy efectiva para prevenir y tratar la enfermedad provocada por un virus de influenza.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130034041 | 2013-03-29 | ||
KR1020130148247A KR20140118682A (ko) | 2013-03-29 | 2013-12-02 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
PCT/KR2014/002691 WO2014158001A1 (ko) | 2013-03-29 | 2014-03-28 | 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013291A MX2015013291A (es) | 2015-12-15 |
MX364312B true MX364312B (es) | 2019-04-22 |
Family
ID=51991477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013291A MX364312B (es) | 2013-03-29 | 2014-03-28 | Composición que comprende al menos dos moléculas neutralizadoras-aglutinadoras del virus de influenza a. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10703802B2 (es) |
EP (1) | EP3011968B1 (es) |
JP (1) | JP6072348B2 (es) |
KR (3) | KR20140118682A (es) |
CN (1) | CN105338994B (es) |
AU (1) | AU2014244668B2 (es) |
CA (1) | CA2902147C (es) |
EA (1) | EA030447B1 (es) |
ES (1) | ES2831802T3 (es) |
IL (1) | IL241881B (es) |
MX (1) | MX364312B (es) |
WO (1) | WO2014158001A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3052192T1 (sl) | 2013-10-02 | 2020-11-30 | Medimmune, Llc | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe |
AU2015289805B2 (en) | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
WO2016089181A1 (ko) * | 2014-12-05 | 2016-06-09 | (주)셀트리온 | 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물 |
US20180008702A1 (en) * | 2014-12-05 | 2018-01-11 | Celltrion Inc. | Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
ES2894777T3 (es) | 2015-06-01 | 2022-02-15 | Medimmune Llc | Neutralización de moléculas de unión anti-influenza y usos de las mismas |
US20190015509A1 (en) * | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
JP6800591B2 (ja) * | 2016-03-11 | 2020-12-16 | 国立大学法人 岡山大学 | インフルエンザ治療剤 |
CN106146657B (zh) * | 2016-07-12 | 2020-07-17 | 晋明(天津)生物医药技术开发有限公司 | 广谱结合流感病毒a的重组抗体片段及其制备方法与应用 |
WO2018030777A1 (ko) * | 2016-08-10 | 2018-02-15 | ㈜셀트리온 | 항-인플루엔자 바이러스 항체의 안정한 액체 약제학적 제제 |
WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
CN107011436B (zh) * | 2017-04-10 | 2019-02-26 | 江苏省疾病预防控制中心 | 抗h7n9病毒的单克隆抗体 |
JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザhaスプリットワクチンの製造方法 |
CN108299316B (zh) * | 2018-01-24 | 2020-03-31 | 山东大学 | 一种抗流感病毒化合物及其制备方法和应用 |
BR112020014849A2 (pt) * | 2018-01-26 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza |
CN108640981A (zh) * | 2018-04-25 | 2018-10-12 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | H7n9亚型流感病毒重组蛋白及病毒疫苗 |
KR20210034614A (ko) * | 2018-07-23 | 2021-03-30 | 국립감염증연구소장이 대표하는 일본국 | 인플루엔자 백신을 포함하는 조성물 |
KR20200060969A (ko) * | 2018-11-23 | 2020-06-02 | (주)셀트리온 | 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법 |
MX2021010685A (es) | 2019-03-04 | 2021-12-10 | Sumitomo Pharma Co Ltd | Método para producir vacuna fraccionada de hemaglutinina (ha) contra la influenza. |
KR102218980B1 (ko) * | 2019-09-18 | 2021-02-23 | 한국생명공학연구원 | 오셀타미비르 내성 인플루엔자 바이러스에 대한 항체 |
KR102373670B1 (ko) * | 2019-09-30 | 2022-03-14 | 중앙대학교 산학협력단 | 신종 인플루엔자 바이러스에 고특이적 고선택적 결합이 가능한 펩타이드 리셉터 및 그를 이용한 바이러스 검출용 바이오칩의 제작방법 |
US20230055468A1 (en) * | 2020-01-10 | 2023-02-23 | University Of Georgia Research Foundation, Inc. | Broadly reactive viral antigens as immunogens, compositions and methods of use thereof |
WO2022216070A1 (ko) * | 2021-04-07 | 2022-10-13 | (주)셀트리온 | 2 이상의 사스-코로나바이러스-2 중화 결합 분자를 포함하는 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008054481A2 (en) | 2006-03-24 | 2008-05-08 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Improved inactivated influenza virus compositions |
EP3333187B1 (en) | 2007-12-06 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
KR101005967B1 (ko) | 2008-04-12 | 2011-01-05 | (주)셀트리온 | 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포 |
WO2010010467A2 (en) | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 dr5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
NZ596032A (en) * | 2009-05-11 | 2013-09-27 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
KR101161810B1 (ko) | 2009-08-21 | 2012-07-03 | 주식회사 효성 | 태양전지의 선택적 에미터 형성방법 및 그 태양전지 제조방법 |
JP2013517789A (ja) | 2010-01-26 | 2013-05-20 | ニプド ジェネティクス リミテッド | 胎児異数性の非侵襲性出生前診断の方法および組成物 |
WO2011111966A2 (en) * | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
WO2011117848A1 (en) * | 2010-03-26 | 2011-09-29 | Pomona Ricerca S.R.L. | Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament |
CN102939103A (zh) * | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
MX346206B (es) * | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
LT3418300T (lt) * | 2011-07-18 | 2021-01-11 | Institute For Research In Biomedicine | Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas |
CN104011077B (zh) | 2011-09-30 | 2017-06-20 | 赛特瑞恩股份有限公司 | 从人b细胞产生的具有甲型流感病毒中和活性的结合分子 |
US9834594B2 (en) * | 2012-09-07 | 2017-12-05 | Celltrion, Inc. | Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses |
-
2013
- 2013-12-02 KR KR1020130148247A patent/KR20140118682A/ko unknown
-
2014
- 2014-03-28 US US14/780,682 patent/US10703802B2/en active Active
- 2014-03-28 MX MX2015013291A patent/MX364312B/es active IP Right Grant
- 2014-03-28 AU AU2014244668A patent/AU2014244668B2/en active Active
- 2014-03-28 ES ES14774436T patent/ES2831802T3/es active Active
- 2014-03-28 CN CN201480018932.7A patent/CN105338994B/zh active Active
- 2014-03-28 EA EA201500854A patent/EA030447B1/ru not_active IP Right Cessation
- 2014-03-28 WO PCT/KR2014/002691 patent/WO2014158001A1/ko active Application Filing
- 2014-03-28 JP JP2016505410A patent/JP6072348B2/ja active Active
- 2014-03-28 EP EP14774436.1A patent/EP3011968B1/en active Active
- 2014-03-28 KR KR1020140036601A patent/KR101681550B1/ko active IP Right Grant
- 2014-03-28 CA CA2902147A patent/CA2902147C/en active Active
-
2015
- 2015-10-06 IL IL241881A patent/IL241881B/en active IP Right Grant
-
2016
- 2016-08-31 KR KR1020160112156A patent/KR102255099B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2014244668B2 (en) | 2016-09-22 |
EP3011968A1 (en) | 2016-04-27 |
IL241881B (en) | 2021-03-25 |
CA2902147A1 (en) | 2014-10-02 |
EP3011968A4 (en) | 2016-11-02 |
EA201500854A1 (ru) | 2015-12-30 |
KR20160115875A (ko) | 2016-10-06 |
KR102255099B1 (ko) | 2021-05-25 |
WO2014158001A1 (ko) | 2014-10-02 |
CA2902147C (en) | 2020-02-11 |
ES2831802T3 (es) | 2021-06-09 |
JP6072348B2 (ja) | 2017-02-01 |
JP2016516090A (ja) | 2016-06-02 |
EA030447B1 (ru) | 2018-08-31 |
KR20140118682A (ko) | 2014-10-08 |
US20160052997A1 (en) | 2016-02-25 |
EP3011968B1 (en) | 2020-08-12 |
KR101681550B1 (ko) | 2016-12-01 |
CN105338994B (zh) | 2018-11-27 |
AU2014244668A1 (en) | 2015-10-01 |
CN105338994A (zh) | 2016-02-17 |
KR20140119641A (ko) | 2014-10-10 |
US10703802B2 (en) | 2020-07-07 |
MX2015013291A (es) | 2015-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015013291A (es) | Composicion que comprende al menos dos moleculas neutralizadoras-aglutinadoras del virus de influenza a. | |
EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
CL2017001798A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas. | |
CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
EA029939B8 (ru) | Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение | |
EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
EA201790266A1 (ru) | Индолы для применения при инфекции, вызванной вирусом гриппа | |
CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
EA201790571A1 (ru) | Пирролопиримидины для применения при инфекции, вызванной вирусом гриппа | |
EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
EA200970916A1 (ru) | Соединения 5,6-дигидро-1н-пиридин-2-она | |
EA201400537A1 (ru) | 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА | |
MX2021004464A (es) | Compuestos de tiazolida para el tratamiento de infecciones virales. | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
EA201891576A1 (ru) | Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа | |
EA201892246A1 (ru) | Производные аминотиазола, полученные в качестве противовирусных средств | |
BR112018073944A2 (pt) | uso de uma composição. | |
BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |